Warfarin and acetaminophen interaction: A summary of the evidence and biologic plausibility

Blood

Volumn 118, Issue 24, 2011, Pages 6269-6273

  Lopes, Renato D ^a   Horowitz, John D ^b   Garcia, David A ^c   Crowther, Mark A ^d   Hylek, Elaine M ^e  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^d MCMASTER UNIVERSITY   (Canada)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450 2E1; N ACETYL 1,4 BENZOQUINONE IMINE; PARACETAMOL; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; CYTOTOXICITY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; EMBOLISM PREVENTION; ENZYME ACTIVATION; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; REVIEW; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

EID: 83455220187     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-335612     Document Type: Review

References (40)

1. Ansell J, Hirsh J, Hylek EM, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133(6 suppl):160S-198S. (Pubitemid 351892967)
2. Connolly SJ, Pogue J, Eikelboom J, et al. ACTIVE W Investigators: benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation. 2008;118(20):2029-2037.
3. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-245.
4. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy. 2004;24(12):1668-1674. (Pubitemid 39578956)
5. Antlitz AM, Mead JA, Tolentino MA. Potentiation of oral anticoagulant therapy by acetaminophen. Curr Ther Res. 1968;10(10):501-507.
6. Bertolini A, Ferrari A, Ottani A, Guerzoni S, Tacchi R, Leone S. Paracetamol: new vistas of an old drug. CNS Drug Rev. 2006(Fall-Winter);12(3): 250-275.
7. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8):1331-1346.
8. Orme M, Breckenridge A, Cook P. Warfarin and distalgesic interaction. Br Med J. 1976;1(6003):200.
9. Bartle WR, Blakely JA. Potentiation of warfarin anticoagulation by acetaminophen. JAMA. 1991;265(10):1260.
10. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;279(9):657-662. (Pubitemid 28138733)
11. Chatap G, Giraud K, Delay V, et al. Factors of therapeutic imbalance of antivitamins K and their haemorrhagic consequences in elderly. Therapie. 2008;63(5):393-401.
12. Shalansky S, Lynd L, Richardson K, Ingaszewski A, Kerr C. Risk of warfarin-related bleeding events and supratherapeutic international normalized ratios associated with complementary and alternative medicine: a longitudinal analysis. Pharmacotherapy. 2007;27(9):1237-1247. (Pubitemid 47339121)
13. Launiainen T, Sajantila A, Rasanen I, Vuori E, Ojanperä I. Adverse interaction of warfarin and paracetamol: evidence from a post-mortem study. Eur J Clin Pharmacol. 2010;66(1):97-103.
14. van den Bemt PM, Geven LM, Kuitert NA, Risselada A, Brouwers JR. The potential interaction between oral anticoagulants and acetaminophen in everyday practice. Pharm World Sci. 2002;24(5):201-204. (Pubitemid 35204297)
15. Gebauer MG, Nyfort-Hansen K, Henschke PJ, Gallus AS. Warfarin and acetaminophen interaction. Pharmacotherapy. 2003;23(1):109-112. (Pubitemid 36077374)
16. Antlitz AM, Awalt LF. A double-blind study of acetaminophen used in conjunction with oral anticoagulant therapy. Curr Ther Res Clin Exp. 1969; 11(6):360-361.
17. Mahé I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol. 2005;59(3):371-374. (Pubitemid 40388092)
18. Mahé I, Bertrand N, Drouet L, et al. Interaction between paracetamol and warfarin in patients: a double-blind, placebo-controlled, randomized study. Haematologica. 2006;91(12):1621-1627. (Pubitemid 46032959)
19. Parra D, Beckey NP, Stevens GR. The effect of acetaminophen on the international normalized ratio in patients stabilized on warfarin therapy. Pharmacotherapy. 2007;27(5):675-683. (Pubitemid 46700959)
20. Zhang Q, Bal-dit-Sollier C, Drouet L, et al. Interaction between acetaminophen and warfarin in adults receiving long-term oral anticoagulants: a randomized controlled trial. Eur J Clin Pharmacol. 2011;67(3):309-314.
21. Kwan D, Bartie WR, Walker SE. The effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 1999;39(1):68-75. (Pubitemid 29053154)
22. Thijssen HH, Soute BA, Vervoort LM, Claessens JG. Paracetamol (acetaminophen) warfarin interaction: NAPQI, the toxic metabolite of paracetamol, is an inhibitor of enzymes in the vitamin K cycle. Thromb Haemost. 2004;92(4):797-802. (Pubitemid 39386707)
23. Whyte IM, Buckley NA, Reith DM, Goodhew I, Seldon M, Dawson AH. Acetaminophen causes an increased international normalized ratio by reducing functional factor VII. Ther Drug Monit. 2000;22(6):742-748.
24. Patten CJ, Thomas PE, Guy RL, et al. Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol. 1993;6(4):511-518. (Pubitemid 23212521)
25. Raucy JL, Lasker JM, Lieber CS, Black M. Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989;271(2):270-283. (Pubitemid 19145373)
26. Hinson JA, Roberts DT, James LP. Mechanisms of acetaminophen-induced liver necrosis. Handb Exp Pharmacol. 2010;196369-405.
27. James LP, Maveaux PR, Hinson JA. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos. 2003;31(12):1499-1506. (Pubitemid 37466918)
28. Das J, Ghosh J, Manna P, Sil PC. Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010;44(3):340-355.
29. Kim SN, Seo JY, Jung da W, Lee MY, Jung YS, Kim YC. Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007;35(10):1754-1758. (Pubitemid 47481566)
30. Knockaert L, Descatoire V, Vadrot N, Fromenty B, Robin MA. Mitochondrial CYP2E1 is sufficient to mediate oxidative stress and cytotoxicity induced by ethanol and acetaminophen. Toxicol In Vitro. 2011;25(2):475-484.
31. Schafer A, Galuppo P, Fraccarollo D, et al. Increased cytochrome P4502E1 expression and altered hydroxyeicosatetraenoic acid formation mediate diabetic vascular dysfunction: rescue by guanylyl-cyclase activation. Diabetes. 2010;59(8):2001-2009.
32. Wong NA, Rae F, Simpson KJ, Murray GD, Harrison DJ. Genetic polymorphisms of cytochrome p4502E1 and susceptibility to alcoholic liver disease and hepatocellular carcinoma in a white population: a study and literature review, including meta-analysis. Mol Pathol. 2000;53(2):88-93. (Pubitemid 30183082)
33. Donnelly PJ, Walker RM, Racz WJ. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity. Arch Toxicol. 1994;68(2):110-118. (Pubitemid 24064840)
34. Hinson JA, Reid AB, McCullough SS, James LP. Acetaminophen-induced hepatotoxicity: role of metabolic activation, reactive oxygen species, and mitochondrial permeability transition. Drug Metab Rev. 2004;36(3):805-822. (Pubitemid 39453075)
35. Bait ML, Knight TR, Farhood A, Jaeschke H. Scavenging peroxynitrite with glutathione promotes regeneration and enhances survival during acetaminophen-induced liver injury in mice. J Pharmacol Exp Ther. 2003;307(1):67-73. (Pubitemid 37151892)
36. Wu D, Cederbaum A. Nitric oxide donors prevent while the nitric oxide synthase inhibitor L-NAME increases arachidonic acid plus CYP2E1-dependent toxicity. Toxicol Appl Pharmacol. 2006;216(2):282-292. (Pubitemid 44466008)
37. Cederbaum A. Nrf2 and antioxidant defense against CYP2E1 toxicity. Expert Opin Drug Metab Toxicol. 2009;5(10):1223-1244.
38. Schulman S, Wang B, Weikal L, Rapoport TA. Vitamin K epoxide reductase prefers ER membrane-anchored thioredoxin-like redox partners. Proc Natl Acad Sci U S A. 2010;107(34):15027-15032.
39. Rishavy MA, Usubalieva A, Hallgren KW, Berkner KL. Electron relay through Cys43 and Cys 51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylation. J Biol Chem. 2011;286(9):7267-7278.
40. Tie JK, Jin DY, Loiselle DR, Pope RM, Straight DL, Stafford DW. Chemical modification of cysteine residues is a misleading indication of their status as active site in the vitamin K-dependent gamma-glutamyl carboxylation reaction. J Biol Chem. 2004;279(52):54079-54087. (Pubitemid 40053142)